Multiple Myeloma: Focus on Clinical Practice in the Era of Molecular Analysis
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 9852

Special Issue Editors
Interests: multiple myeloma; amyloidosis AL; monoclonal gammopathies; epidemiology; genomics; prognosis; therapy
Special Issue Information
Dear Colleagues,
Multiple myeloma (MM) is a complex, heterogeneous and challenging disease. Population-based cancer registries have sharpened our knowledge on risk factors, incidence, prevalence, mortality and survival in the real-world setting. A myriad of cutting-edge clinical trials has allowed for constant progress in the outcome of patients, in terms of survival and quality of life. Consequently, clinicians witness a dizzying change in the therapy guidelines, sometimes difficult to translate to daily clinical practice. On the other hand, next-generation flow, next-generation sequencing, mass-spectrometry and multi-omics large-scale studies are deciphering the keys to the interplay between the plasma cell clone, the medullary microenvironment and the damaged immune system. A comprehensive assessment of prognosis should consider host factors (particularly, comorbidity and frailty), disease factors (remarkably, circulating tumor cells, immunoparesis, extramedullary disease and high-risk disease), staging and, last but not least, the response to therapy (especially the minimal measurable disease). Most of these evaluations are far from being standardized. Artificial intelligence is playing a critical role in helping with this increasingly multifaceted task. Both diagnostic and response criteria should be adapted to this new scenario. Further biomarkers are needed in order to achieve an accurate and timely diagnosis and prognosis assessment. Remarkably, infection remains a leading cause of morbidity and mortality in MM.
Overall, a deeper knowledge of the immune system is the basis for the current immunotherapy-based approach to therapy. Despite the impressive advancement, MM remains an incurable disease. Drug resistance is a key obstacle to find the road to cure MM. The management of relapse and refractory disease, focusing on triple or more refractory patients is a challenge, in which, again, an immunotherapy-based approach, such as new bispecific antibodies and new generations of CAR-T, is now leading the battle.
The aim of this Special Issue is to give updated insights about the previously mentioned hot topics and unmet clinical needs for this devastating disease.
Dr. Rafael Ríos-Tamayo
Dr. Juan José Lahuerta
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.